322 related articles for article (PubMed ID: 36267540)
21. Successful single treatment with ziv-aflibercept for existing corneal neovascularization following ocular chemical insult in the rabbit model.
Gore A; Horwitz V; Cohen M; Gutman H; Cohen L; Gez R; Kadar T; Dachir S
Exp Eye Res; 2018 Jun; 171():183-191. PubMed ID: 29548928
[TBL] [Abstract][Full Text] [Related]
22. Anti-VEGF Treatment in Corneal Diseases.
Giannaccare G; Pellegrini M; Bovone C; Spena R; Senni C; Scorcia V; Busin M
Curr Drug Targets; 2020; 21(12):1159-1180. PubMed ID: 32189591
[TBL] [Abstract][Full Text] [Related]
23. Gene transfer for the treatment of neovascular ocular disease (an American Ophthalmological Society thesis).
Stout JT
Trans Am Ophthalmol Soc; 2006; 104():530-60. PubMed ID: 17471360
[TBL] [Abstract][Full Text] [Related]
24. Tumor necrosis factor-α inhibitors as a treatment of corneal hemangiogenesis and lymphangiogenesis.
Ferrari G; Bignami F; Rama P
Eye Contact Lens; 2015 Mar; 41(2):72-6. PubMed ID: 25503908
[TBL] [Abstract][Full Text] [Related]
25. Acidic/neutral amino acid residues substitution in NH2 terminal of plasminogen kringle 5 exerts enhanced effects on corneal neovascularization.
Li C; Li L; Cheng R; Dai Z; Li C; Yao Y; Zhou T; Yang Z; Gao G; Yang X
Cornea; 2013 May; 32(5):680-8. PubMed ID: 23343948
[TBL] [Abstract][Full Text] [Related]
26. Clinico-biochemical correlation of the effect of subconjunctival bevacizumab for corneal neovascularization.
Agarwal S; Angayarkanni N; Iyer G; Srinivasan B; Natarajan R; Charola S; Arumugam S; Padmanabhan P
Cornea; 2014 Oct; 33(10):1016-21. PubMed ID: 25090164
[TBL] [Abstract][Full Text] [Related]
27. [Current treatments for corneal neovascularization].
Benayoun Y; Petellat F; Leclerc O; Dost L; Dallaudière B; Reddy C; Robert PY; Salomon JL
J Fr Ophtalmol; 2015 Dec; 38(10):996-1008. PubMed ID: 26522890
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the antiangiogenic activity of modified RGDRGD-endostatin to endostatin delivered by gene transfer in vivo rabbit neovascularization model.
Ge HY; Xiao N; Yin XL; Fu SB; Ge JY; Shi Y; Liu P
Mol Vis; 2011; 17():1918-28. PubMed ID: 21850166
[TBL] [Abstract][Full Text] [Related]
29. Corneal neovascularization is inhibited with nucleolin-binding aptamer, AS1411.
Vivanco-Rojas O; García-Bermúdez MY; Iturriaga-Goyon E; Rebollo W; Buentello-Volante B; Magaña-Guerrero FS; Bates P; Pérez-Torres A; Garfias Y
Exp Eye Res; 2020 Apr; 193():107977. PubMed ID: 32081668
[TBL] [Abstract][Full Text] [Related]
30. Broad spectrum antiangiogenic treatment for ocular neovascular diseases.
Benny O; Nakai K; Yoshimura T; Bazinet L; Akula JD; Nakao S; Hafezi-Moghadam A; Panigrahy D; Pakneshan P; D'Amato RJ
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20824139
[TBL] [Abstract][Full Text] [Related]
31. Imidazole-based alkaloid derivative LCB54-0009 suppresses ocular angiogenesis and lymphangiogenesis in models of experimental retinopathy and corneal neovascularization.
Kim BH; Lee J; Choi JS; Park DY; Song HY; Park TK; Cho CH; Ye SK; Joo CK; Koh GY; Kim TY
Br J Pharmacol; 2015 Aug; 172(15):3875-89. PubMed ID: 25917462
[TBL] [Abstract][Full Text] [Related]
32. A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents.
Hosseini H; Nejabat M
Med Hypotheses; 2007; 68(4):799-801. PubMed ID: 17107753
[TBL] [Abstract][Full Text] [Related]
33. Ocular lamellar crystalline gels for sustained release and enhanced permeation of resveratrol against corneal neovascularization.
Li M; Yu X; Zhu L; Jin Y; Wu Z
Drug Deliv; 2021 Dec; 28(1):206-217. PubMed ID: 33472443
[TBL] [Abstract][Full Text] [Related]
34. [Novel approach for management of age-related macular degeneration--antiangiogenic therapy and retinal regenerative therapy].
Tamaki Y
Nippon Ganka Gakkai Zasshi; 2007 Mar; 111(3):232-68; discussion 269. PubMed ID: 17402564
[TBL] [Abstract][Full Text] [Related]
35.
Estrella-Mendoza MF; Jiménez-Gómez F; López-Ornelas A; Pérez-Gutiérrez RM; Flores-Estrada J
Nutrients; 2019 May; 11(5):. PubMed ID: 31137826
[TBL] [Abstract][Full Text] [Related]
36. A robust model for simultaneously inducing corneal neovascularization and retinal gliosis in the mouse eye.
Paranthan RR; Bargagna-Mohan P; Lau DL; Mohan R
Mol Vis; 2011; 17():1901-8. PubMed ID: 21850164
[TBL] [Abstract][Full Text] [Related]
37. Corticosteroids as antiangiogenic agents.
Oliver A; Ciulla TA
Ophthalmol Clin North Am; 2006 Sep; 19(3):345-51, v. PubMed ID: 16935209
[TBL] [Abstract][Full Text] [Related]
38. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization.
Koenig Y; Bock F; Horn F; Kruse F; Straub K; Cursiefen C
Graefes Arch Clin Exp Ophthalmol; 2009 Oct; 247(10):1375-82. PubMed ID: 19415316
[TBL] [Abstract][Full Text] [Related]
39. Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation.
Shokirova H; Inomata T; Saitoh T; Zhu J; Fujio K; Okumura Y; Yanagawa A; Fujimoto K; Sung J; Eguchi A; Miura M; Nagino K; Hirosawa K; Kuwahara M; Akasaki Y; Nagase H; Murakami A
Sci Rep; 2021 Apr; 11(1):8647. PubMed ID: 33883646
[TBL] [Abstract][Full Text] [Related]
40. [Antiangiogenic therapy at the ocular surface: when, what and why?].
Bock F; Regenfuss B; Cursiefen C
Ophthalmologe; 2011 Mar; 108(3):230-6. PubMed ID: 21271256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
